Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib for advanced refractory non-small cell lung cancer
ChiCTR-OPC-17011020Phase 4Recruiting
- Sponsor
- 904th Hospital of the Joint Logistic Support Force
- Start
- Jan 1990
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by 904th Hospital of the Joint Logistic Support Force. Primary endpoints: Disease control rate (DCR), Objective response rate (ORR) and 1 more. Started Jan 1990; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-OPC-17011020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17011020.